Table 1.

The association between Prp19 expression with clinical pathologic characteristics in the TMA cohort.

Clinical and pathological characteristics	Total	Prp19		χ2	P
		High	Low
Gender
Male	35	14	21	2.264	0.132
Female	27	16	11
Age at diagnosis
≥18 months	42	21	21	0.136	0.713
<18 months	20	9	11
Bone marrow metastasis
Positive	21	15	6	6.751	0.009
Negative	41	15	26
Clinical stages
I–II IV–S	25	10	15	1.180	0.277
III–IV	37	20	17
Diagnostic category
NB and GNB-N	43	25	18	5.344	0.021
GNB-I	19	5	14
Shimada pathologic type
FH	30	10	20	5.274	0.022
UFH	32	20	12
Risk classification
Low and
Intermediate	34	12	22	5.168	0.023
High	28	18	10

NB, neuroblastoma; GNB-N, ganglioneuroblastoma-nodular; GNB-I, ganglioneuroblastoma-intermixed; FH, favorable histology; UFH, unfavorable histology.